News | December 06, 2007

Edwards Lifesciences to Sell LifeStent for $140 Million

December 7, 2007 - Edwards Lifesciences Corp. today has entered into a definitive agreement to sell certain assets related to the Edwards LifeStent peripheral vascular product line to C.R. Bard Inc. for up to $140 million. The transaction is expected to close in January 2008, pending regulatory approvals.

"Although sales are growing, the LifeStent product line is generating operating losses," said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. "This transaction enables Edwards to increase our investments in the exciting opportunities in our market-leading heart valve and critical care businesses. Achieving leadership in the peripheral vascular market would have required substantial additional investment, which can now be directed to our core businesses."

Under the terms of the agreement, Edwards will receive an initial cash payment of approximately $75 million at closing, plus an additional $65 million in cash upon the achievement of certain milestones, including the receipt of U.S. regulatory approval of Edwards' LifeStent products for a superficial femoral artery indication and the transfer of LifeStent device manufacturing. For 2007, this business represents approximately $30 million in sales.

Edwards will provide transition services for a period of up to two and a half years following the closing. Approximately 150 employees may be affected by the end of the transition.

"We would like to express our sincere gratitude to our dedicated employees along with the committed clinicians in this field with whom we have had the opportunity to work over the past several years. We clearly recognize the value that has been created as a result of their efforts to improve the care of patients suffering from peripheral vascular disease," said Mussallem. "We are pleased that patients will continue to benefit from this technology under the new ownership."

For more information: www.edwards.com

Related Content

Intact Vascular Announces $20 Million Series C Financing
News | Stents Peripheral | April 27, 2018
April 27, 2018 — Intact Vascular Inc. recently closed a Series C financing totaling $20 million.
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral | July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral | July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
New Twelve-Month Data Show Efficacy of Pulsar-18 Bare Metal Stent
News | Stents Peripheral | April 28, 2017
Biotronik’s Pulsar-18 bare metal stent (BMS) has yielded high primary patency in a real-world setting, according to the...
Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease
News | Stents Peripheral | March 16, 2017
W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a...
TOBA II BTK clinical trial, Intact Vascular, Tack Endovascular System, CLI, critical limb ischemia, first patient treated
News | Stents Peripheral | March 02, 2017
Intact Vascular Inc. announced in February that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
Biotronik, Pulsar-18 bare metal self-expanding stent, BMS SE, BIOFLEX PEACE trial, 12-month results, VEITHsymposium 2016
News | Stents Peripheral | December 13, 2016
Biotronik announced the presentation of data confirming the efficacy of the Pulsar-18 bare metal self-expanding stent (...
LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral | December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Gore, Tigris stent, fluoropolymer nitinol stent, peripheral artery disease

The Gore Tigris is a dual-component stent with a unique fluoropolymer / nitinol design.

Technology | Stents Peripheral | August 02, 2016
August 2, 2016 —The U.S. Food and Drug Administration (FDA) granted market clearance for W. L.
Technology | Stents Peripheral | April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Overlay Init